Links from this page to related variants, conditions, drugs and topics are not included for automated readers. Those connections are the Gene Knowledge Graph and are licensed as data: https://www.mygenelog.com/license

Musculoskeletal

Hip Osteoarthritis

Reviewed September 16, 2026

A joint-specific genetics story: hip osteoarthritis does not share its loci with knee osteoarthritis, and the gene behind this page's lead signal is not just statistically associated but measurably less active in the cartilage the disease damages.

What this condition connects to

Prevalence
A two-stage meta-analysis of genome-wide association studies in over 78,000 participants, including 11,277 cases of hip osteoarthritis, found rs6094710 near NCOA3 associated at genome-wide significance (odds ratio 1.28), with NCOA3 shown to be expressed in articular cartilage and significantly reduced in osteoarthritis-affected cartilage. A second, male-specific suggestive signal was found near CAMK2B (Castaño Betancourt et al., Annals of the Rheumatic Diseases 2014, PMID 23989986).
Inheritance
Common variants, each shifting risk by a small amount, joint-specific in their effect. Distinct from the rare, high-penetrance mutations that cause syndromic forms of early-onset osteoarthritis.

Osteoarthritis is the wearing down of the cartilage that cushions a joint, leading to pain, stiffness and reduced movement. Its genetics are joint-specific — a locus found for hip osteoarthritis does not generally turn out to matter for the knee, and this site's knee osteoarthritis page holds a different variant entirely. That is why hip gets its own page rather than a subtype note on that one.

A signal checked against the tissue itself

The study behind this page was a two-stage meta-analysis of genome-wide association studies covering over 78,000 participants and 11,277 cases of hip osteoarthritis, confirmed by X-ray and symptoms. Its lead signal, rs6094710 near NCOA3 (nuclear receptor coactivator 3), carried an odds ratio of 1.28.

What makes this one worth reading past the statistic is what the researchers did next: they checked whether NCOA3 is actually expressed in articular cartilage — the tissue osteoarthritis damages — and whether that expression changes with disease. It is expressed there, and its expression is significantly reduced in osteoarthritis-affected cartilage compared with healthy tissue. A statistical association does not have to come with biological evidence like that; when it does, the signal is easier to believe.

The second variant, rs3757837 near CAMK2B, was a suggestive, male-specific signal in the same study, with a minor allele frequency of about 6% and an odds ratio of 1.27 in the male-specific analysis — smaller, less certain, and worth stating as such.

Clinical detail

What actually diagnoses and treats hip osteoarthritis

Diagnosis rests on symptoms — hip or groin pain, stiffness, reduced range of motion — and X-ray findings of joint space narrowing and bone changes. Management is symptom-driven: weight management, physiotherapy and exercise, pain relief, and joint replacement surgery when the joint is severely damaged and other measures no longer help. None of it depends on a genotype.

What this page cannot do. The two variants here shift risk by a small amount each and do not diagnose the disease. Hip or groin pain that persists, especially with stiffness after rest, is what should prompt an evaluation — an X-ray, not a genotype, confirms osteoarthritis.

Sex-specific findings deserve the caveat they get

The CAMK2B signal reached significance only in a male-specific analysis. Sex-stratified findings from a single study are a weaker form of evidence than a signal that holds in everyone, and this page states that difference rather than presenting both variants as equivalent.

What this page cannot do

  • It cannot diagnose hip osteoarthritis. Symptoms and an X-ray do.
  • It cannot predict who needs joint replacement. That is decided by how much a damaged joint is limiting someone's life, assessed clinically over time.
  • It cannot be compared to the knee osteoarthritis page as if the two diseases shared genetics. They largely do not.

Which ancestries this evidence comes from

The studies behind these variants recruited participants from different ancestries — a result found in one population doesn't always transfer to another. Based on 6 of 28 linked studies with a resolved discovery ancestry.

European · 21.4% Not yet resolved · 78.6%

Sources

Databases, guidelines and references

Papers, with their authors

Quoting this page

Licensed CC BY-NC 4.0: free to read, share and adapt for non-commercial use, naming MyGeneLog™ and linking the exact page. Commercial use, including training or serving a commercial AI system, needs a licence — https://www.mygenelog.com/license

Hip Osteoarthritis. MyGeneLog™. https://www.mygenelog.com/conditions/hip-osteoarthritis

Questions about Hip Osteoarthritis

Can a DNA test tell me if I have hip osteoarthritis?

No. The two variants here each shift risk by a small amount and neither detects the disease. Persistent hip or groin pain and stiffness, evaluated with an X-ray, is how hip osteoarthritis is actually diagnosed.

Does the NCOA3 finding mean there could be a treatment target here?

It is a genuine mechanistic clue — the gene is expressed in the right tissue and its expression drops in disease — but the study did not establish what restoring that expression would do, and nothing here is used as a treatment target today.

I am male. Does the CAMK2B variant matter more for me?

It is a suggestive signal found only in a male-specific analysis of one study, which is weaker evidence than a signal confirmed in everyone. It is worth knowing the caveat exists, not treating the finding as settled.

Why is this a separate page from knee osteoarthritis?

Because the genetics are largely joint-specific — the loci found for hip osteoarthritis are not the same ones found for the knee, and this site holds a different variant on each page for that reason.

Free to reuse, non-commercially. This page's text is original writing from freely-available research, licensed CC BY-NC 4.0 — share and adapt it with attribution to MyGeneLog™; commercial use is licensed. It's general research-derived information, not medical advice or a diagnosis — see Terms of Use.